cholestyramine resin has been researched along with Hyperlipoproteinemia Type III in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (81.82) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hui, DY; Innerarity, TL; Mahley, RW | 1 |
| Durrington, PN; Miller, JP | 1 |
| Andersén, E | 1 |
| Göring, HD; Ziemer, A | 1 |
| Frants, RR; Havekes, LM; Hoffer, MJ; Kibirige, MS; Naoumova, RP; Niththyananthan, S; Thompson, GR | 1 |
| Havel, RJ | 1 |
| Houlston, R; Lewis, B; Quiney, J; Watts, GF | 1 |
| Breslow, JL; Eisenberg, S; Weintraub, MS | 1 |
| Gotto, AM; Jones, PH; Scott, LW | 1 |
| Levy, RI; Schaefer, EJ | 1 |
| Parker, F | 1 |
4 review(s) available for cholestyramine resin and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Clinical aspects of hyperlipidaemia.
Topics: Adult; Child; Cholestyramine Resin; Chylomicrons; Coronary Disease; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lipoproteins; Lipoproteins, HDL; Xanthomatosis | 1984 |
Functional activities of hepatic lipoprotein receptors.
Topics: Animals; Binding Sites; Cholesterol, Dietary; Cholestyramine Resin; Chylomicrons; Dogs; Endocytosis; Estradiol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Mutation; Rabbits; Rats; Receptors, Cell Surface; Receptors, LDL; Receptors, Lipoprotein | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibrate; Colestipol; Coronary Disease; Dextrothyroxine; Dietary Fats; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Lipoproteins; Lipoproteins, LDL; Neomycin; Niacin; Pentanoic Acids; Probucol; Receptors, LDL; Triglycerides | 1986 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylomicrons; Colestipol; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Hypobetalipoproteinemias; Hypolipoproteinemias; Infant; Infant, Newborn; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Tangier Disease | 1985 |
7 other study(ies) available for cholestyramine resin and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E.
Topics: Animals; Apolipoprotein E2; Apolipoprotein E3; Apolipoproteins; Apolipoproteins B; Apolipoproteins E; Calcium; Cholestyramine Resin; Dogs; Humans; Hyperlipoproteinemia Type III; Lipoproteins, VLDL; Liver; Low Density Lipoprotein Receptor-Related Protein-1; Receptors, Cell Surface; Receptors, Lipoprotein | 1984 |
On the metabolism of cholesterol and bile acids in normo- and hyperlipidaemic subjects.
Topics: Bile Acids and Salts; Cholesterol; Cholestyramine Resin; Circadian Rhythm; Diabetes Mellitus; Dietary Carbohydrates; Dietary Fats; Humans; Hyperlipidemias; Hyperlipoproteinemia Type III; Lipid Metabolism; Triglycerides | 1980 |
[Severe type III hyperlipoproteinemia with unusual lipoprotein phenotype in an adolescent patient].
Topics: Adolescent; Apolipoprotein E2; Apolipoproteins E; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Female; Foam Cells; Homozygote; Humans; Hyperlipoproteinemia Type III; Lovastatin; Phenotype; Skin; Triglycerides | 1993 |
Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Cysteamine; Dinucleotide Repeats; DNA; Electrophoresis; Exons; Female; Fenofibrate; Genotype; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Immunoblotting; Male; Nuclear Family; Phenotype; Point Mutation; Radiation-Protective Agents; Triglycerides | 1996 |
Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
Topics: Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Male; Pentanoic Acids; Triglycerides; Valerates | 1988 |
Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
Topics: Cholestyramine Resin; Chylomicrons; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Pentanoic Acids; Triglycerides; Valerates; Vitamin A | 1987 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Diabetes Complications; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Hypolipidemic Agents; Hypothyroidism; Kidney Diseases; Lipoproteins; Male; Neomycin; Niacin; Obesity; Pancreatitis; Xanthomatosis | 1985 |